Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety follow-up after prior romosozumab treatment in pediatric osteogenesis imperfecta
2023-503293-21-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of romosozumab in osteogenesis imperfecta (OI), sponsored by Amgen. Primary endpoint: Adverse events. Planned start Mar 2026; status: authorised.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on 2023-503293-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503293-21-00.